Market Cap 5.61B
Revenue (ttm) 3.70B
Net Income (ttm) 280.09M
EPS (ttm) N/A
PE Ratio 20.81
Forward PE 21.02
Profit Margin 7.57%
Debt to Equity Ratio 0.07
Volume 310,800
Avg Vol 380,694
Day's Range N/A - N/A
Shares Out 34.29M
Stochastic %K 43%
Beta 0.19
Analysts Sell
Price Target $175.50

Company Profile

FTI Consulting, Inc. provides business advisory services to manage change, mitigate risk, and resolve disputes worldwide. The company operates through Corporate Finance & Restructuring; Forensic and Litigation Consulting; Economic Consulting; and Technology, and Strategic Communications segments. The Corporate Finance & Restructuring segment provides business transformation and strategy, transactions, and turnaround and restructuring services. The Forensic and Litigation Consulting segment offer...

Industry: Consulting Services
Sector: Industrials
Phone: 202 312 9100
Fax: 202 312 9101
Address:
555 12th Street NW, Suite 700, Washington, United States
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 14 at 5:05 AM
$LMDX $RHHBY $FCN $NDAQ Calling All Attorneys Looking for A Easy Win. Heres everything laid out…. go get it! TB TEST IS THE KICKER….
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 14 at 5:02 AM
$LMDX $FCN $RHHBY $NDAQ 🔹 Misleading Market Communication 26. 2023 earnings calls and filings gave false confidence (“path to profitability”). 27. TB test, a globally relevant innovation, was never valued or accounted for. 28. Roche deal framed as minor, but clearly encompassed transformative tech. 29. No SEC complaint disclosures, despite being aware of internal conflicts. 30. Deliberate obfuscation of company value to force fire sale to insiders.
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 14 at 5:02 AM
$LMDX $FCN $RHHBY $NDAQ ⸻ 🔹 Regulatory & Disclosure Failures 20. Failure to file required SEC disclosures (e.g., Form 25, final 20-F, 8-Ks). 21. Misuse of foreign liquidation (Cayman) to avoid U.S. shareholder rights. 22. No public S-4 or material filing disclosing full Roche terms. 23. Continued patent activity post-dissolution, showing hidden residual value. 24. Cayman-based JOLs (liquidators) ignored shareholder inquiries. 25. TB test was awarded patent post-sale, but was in the pipeline during the deal. ⸻
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 14 at 5:01 AM
$LMDX $FCN $RHHBY $NDAQ 12. Use of Jaiventures Ltd and related entities to hold shares/options in secret. 13. Patent assignments and licenses to insider-linked entities before wind-down. ⸻ 🔹 Asset Transfers & Fraudulent Conveyance 14. Valuable IP transferred without compensation to shareholders. 15. Subsidiaries (e.g., Colombia, GmbH) sold for pennies to creditors. 16. ElectraDx, Invita, and SureSensors received tech/IP assets off-book. 17. Use of shell entities and offshore subsidiaries to mask asset flow. 18. Lack of transparency on IP retained or sold in the Roche deal. 19. No accounting of assets in liquidation filings.
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 14 at 4:59 AM
$LMDX $FCN $RHHBY $NDAQ 🔹 Governance & Fiduciary Failures 1. Material misrepresentation of pipeline value (e.g., TB test, new platforms). 2. No shareholder vote or consent on asset sales or liquidation. 3. Executives with conflicts of interest (e.g., Veronique Ameye) oversaw wind-down. 4. Executive bonuses paid during collapse, while shareholders got zero. 5. No fairness opinion or independent valuation provided for Roche deal. 6. Coordinated resignations and job shifts by insiders during wind-down. 7. Breach of fiduciary duty through preferential insider treatment. ⸻ 🔹 Insider Enrichment & Preferential Deals 8. Selective royalty rights granted (e.g., Willard Umphrey). 9. Insider equity acquisitions timed suspiciously (e.g., Umphrey’s share purchase). 10. Founders and former executives reappeared in spinouts (e.g., ElectraDx, SureSensors). 11. Insiders benefited from patents and IP post-dissolution.
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 11 at 11:47 AM
$FCN $LMDX $NDAQ $RHHBY All the above?
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 11 at 10:07 AM
$LMDX $RHHBY $FCN $NDAQ • A formal demand for the IP schedule and transaction details • A whistleblower complaint to the SEC and/or FCA • A shareholder letter of claim for fiduciary breach and unjust enrichment Which one do we move forward with?
1 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 11 at 10:05 AM
$LMDX $RHHBY $FCN $SPY #gatesfoundation #billgates 5. Roche’s “Clean Hands” Facade • Roche acquired transformative diagnostics—including TB, SureSensors’ microfluidics, and a global IP platform—for pennies on the dollar. • The patent issuance date was after the sale, but the technology was not new. It was developed with LMDX shareholder funds. Red Flag: Roche may not have stolen it directly—but they absolutely knowingly benefited from a distressed asset transfer that was not at arm’s length.
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 11 at 10:04 AM
$LMDX $FCN $RHHBY $NDAQ 4. SEC Filings and Shareholder Deception • Public filings continued to promote pipeline optimism through 2023—with zero warning of impending insolvency. • No 8-K or material event filing explained the sudden collapse—despite shareholders being completely wiped out. Red Flag: That’s securities fraud—plain and simple. Material omissions, deceptive optimism, and insider timing.
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 11 at 10:03 AM
$LMDX $FCN $RHHBY $SPY 3. Pre-Pack Administration as a Smokescreen • The UK pre-pack was executed without full creditor or shareholder visibility. • Assets—including IP in the pipework, licenses, and partnerships—were sold without transparent bidding, valuation, or accountability. Red Flag: Pre-packs are legal tools—but in this case, the process shielded insiders from scrutiny. That’s deliberate obfuscation.
0 · Reply
Latest News on FCN
FTI Consulting Announces Technology Alliance with BigID

May 20, 2025, 7:30 AM EDT - 2 months ago

FTI Consulting Announces Technology Alliance with BigID


FTI Consulting, Inc. (FCN) Q1 2025 Earnings Call Transcript

Apr 24, 2025, 5:35 PM EDT - 2 months ago

FTI Consulting, Inc. (FCN) Q1 2025 Earnings Call Transcript


FTI Consulting Reports First Quarter 2025 Financial Results

Apr 24, 2025, 7:30 AM EDT - 3 months ago

FTI Consulting Reports First Quarter 2025 Financial Results


Compass Lexecon Further Enhances Leading Academic Expertise

Apr 2, 2025, 7:30 AM EDT - 3 months ago

Compass Lexecon Further Enhances Leading Academic Expertise


lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 14 at 5:05 AM
$LMDX $RHHBY $FCN $NDAQ Calling All Attorneys Looking for A Easy Win. Heres everything laid out…. go get it! TB TEST IS THE KICKER….
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 14 at 5:02 AM
$LMDX $FCN $RHHBY $NDAQ 🔹 Misleading Market Communication 26. 2023 earnings calls and filings gave false confidence (“path to profitability”). 27. TB test, a globally relevant innovation, was never valued or accounted for. 28. Roche deal framed as minor, but clearly encompassed transformative tech. 29. No SEC complaint disclosures, despite being aware of internal conflicts. 30. Deliberate obfuscation of company value to force fire sale to insiders.
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 14 at 5:02 AM
$LMDX $FCN $RHHBY $NDAQ ⸻ 🔹 Regulatory & Disclosure Failures 20. Failure to file required SEC disclosures (e.g., Form 25, final 20-F, 8-Ks). 21. Misuse of foreign liquidation (Cayman) to avoid U.S. shareholder rights. 22. No public S-4 or material filing disclosing full Roche terms. 23. Continued patent activity post-dissolution, showing hidden residual value. 24. Cayman-based JOLs (liquidators) ignored shareholder inquiries. 25. TB test was awarded patent post-sale, but was in the pipeline during the deal. ⸻
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 14 at 5:01 AM
$LMDX $FCN $RHHBY $NDAQ 12. Use of Jaiventures Ltd and related entities to hold shares/options in secret. 13. Patent assignments and licenses to insider-linked entities before wind-down. ⸻ 🔹 Asset Transfers & Fraudulent Conveyance 14. Valuable IP transferred without compensation to shareholders. 15. Subsidiaries (e.g., Colombia, GmbH) sold for pennies to creditors. 16. ElectraDx, Invita, and SureSensors received tech/IP assets off-book. 17. Use of shell entities and offshore subsidiaries to mask asset flow. 18. Lack of transparency on IP retained or sold in the Roche deal. 19. No accounting of assets in liquidation filings.
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 14 at 4:59 AM
$LMDX $FCN $RHHBY $NDAQ 🔹 Governance & Fiduciary Failures 1. Material misrepresentation of pipeline value (e.g., TB test, new platforms). 2. No shareholder vote or consent on asset sales or liquidation. 3. Executives with conflicts of interest (e.g., Veronique Ameye) oversaw wind-down. 4. Executive bonuses paid during collapse, while shareholders got zero. 5. No fairness opinion or independent valuation provided for Roche deal. 6. Coordinated resignations and job shifts by insiders during wind-down. 7. Breach of fiduciary duty through preferential insider treatment. ⸻ 🔹 Insider Enrichment & Preferential Deals 8. Selective royalty rights granted (e.g., Willard Umphrey). 9. Insider equity acquisitions timed suspiciously (e.g., Umphrey’s share purchase). 10. Founders and former executives reappeared in spinouts (e.g., ElectraDx, SureSensors). 11. Insiders benefited from patents and IP post-dissolution.
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 11 at 11:47 AM
$FCN $LMDX $NDAQ $RHHBY All the above?
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 11 at 10:07 AM
$LMDX $RHHBY $FCN $NDAQ • A formal demand for the IP schedule and transaction details • A whistleblower complaint to the SEC and/or FCA • A shareholder letter of claim for fiduciary breach and unjust enrichment Which one do we move forward with?
1 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 11 at 10:05 AM
$LMDX $RHHBY $FCN $SPY #gatesfoundation #billgates 5. Roche’s “Clean Hands” Facade • Roche acquired transformative diagnostics—including TB, SureSensors’ microfluidics, and a global IP platform—for pennies on the dollar. • The patent issuance date was after the sale, but the technology was not new. It was developed with LMDX shareholder funds. Red Flag: Roche may not have stolen it directly—but they absolutely knowingly benefited from a distressed asset transfer that was not at arm’s length.
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 11 at 10:04 AM
$LMDX $FCN $RHHBY $NDAQ 4. SEC Filings and Shareholder Deception • Public filings continued to promote pipeline optimism through 2023—with zero warning of impending insolvency. • No 8-K or material event filing explained the sudden collapse—despite shareholders being completely wiped out. Red Flag: That’s securities fraud—plain and simple. Material omissions, deceptive optimism, and insider timing.
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 11 at 10:03 AM
$LMDX $FCN $RHHBY $SPY 3. Pre-Pack Administration as a Smokescreen • The UK pre-pack was executed without full creditor or shareholder visibility. • Assets—including IP in the pipework, licenses, and partnerships—were sold without transparent bidding, valuation, or accountability. Red Flag: Pre-packs are legal tools—but in this case, the process shielded insiders from scrutiny. That’s deliberate obfuscation.
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 11 at 10:01 AM
$LMDX $FCN $RHHBY $SPY 2. Insider Enrichment During Collapse • Zwanziger resigned citing “conflict of interest” over shareholding—then helped fund or control ElectraDx, using ex-LumiraDx assets and staff. • Veronique Ameye, a long-trusted insider, managed the liquidation pre and post and then moved into an executive role adjacent to Roche, after ensuring the asset transfer occurred cleanly. If that isn’t conflict of interest I don’t know what is…
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 11 at 9:59 AM
$LMDX $FCN $RHHBY $NDAQ q It’s not over. You all know it. This will be a payout or a court case win. 1. Asset Concealment & Transfer • The TB diagnostic patent was awarded after the Roche deal but developed before—and nowhere valued in the transaction. • This is classic fraudulent conveyance: transferring valuable assets for little or no consideration, especially to insiders or favored third parties. Red Flag: Concealing material IP during liquidation is actionable under both UK insolvency law and U.S. shareholder protections.
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 10 at 2:59 AM
$LMDX $RHHBY $FCN $NDAQ While shareholders were misled and wiped out, insiders walked away with patents, royalty streams, and new corporate appointments. That’s not restructuring—it’s corporate looting.
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 10 at 2:58 AM
$LMDX $NDAQ $RHHBY $FCN This was not a sale—it was a sanctioned asset heist dressed up as an insolvency proceeding.
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 10 at 2:56 AM
$LMDX $FCN $RHHBY $NDAQ Misrepresentation in SEC Filings • As late as mid-2023, LumiraDx was publicly reporting ongoing development of next-gen tests (e.g., TB, RSV, Strep A). • No warning of pending liquidation or strategic dismantling was made public until after insiders secured their positions. LMDX insiders misled shareholders with false or incomplete filings, failing to disclose the company’s true financial condition and intent to dissolve. But what was their real plan?
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 10 at 2:54 AM
$LMDX $FCN $RHHBY $NDAQ Deliberate Use of UK Pre-Pack Administration • The asset sale was done via a UK “pre-pack” insolvency—no shareholder vote, no public auction, no formal asset valuation process. • The TB test, SureSensors, and other advanced pipeline assets were effectively given away or siloed into new entities. That process was used to bypass shareholder rights, and that a fair-market value process would have returned material value to investors.
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 10 at 2:52 AM
$LMDX $FCN $RHHBY $SPY 1. TB Patent Concealment • The tuberculosis patent (US 11,789,021) was issued after the Roche acquisition but was developed prior. • It should have been valued as a pending asset in the transaction. • There’s no disclosure to shareholders that this patent—or the underlying technology—was being sold, monetized, or separately licensed. This proves that insiders deliberately failed to disclose or value a material asset, which was then quietly transferred to Roche—constituting fraudulent conveyance or breach of fiduciary duty.
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jul. 10 at 2:49 AM
$LMDX $RHHBY $SPY $FCN Patent in process ≠ valueless: If the TB test was in development and the patent was pending at the time of the sale, it should have been disclosed as a material asset in the pipeline. Even unissued patents are recognizable intangible assets in M&A due diligence. Failure to disclose material IP to shareholders may constitute: • Breach of fiduciary duty • Violation of disclosure requirements • Improper asset undervaluation during insolvency proceedings
0 · Reply
UncleStock
UncleStock Jun. 1 at 8:15 PM
$CUBI $FCN $BRPHF suggested for #blockchain - value screen: https://zpr.io/nAuVa
0 · Reply
smartkarma
smartkarma May. 7 at 12:10 PM
$FCN | FCN US: Segment Performance & Revenue Diversity As a Crucial Factor For Sustained Performance! "FTI Consulting delivered a mixed set of results for the first quarter of 2025 with both positive highlights and some areas of concern." - Baptista Research (Baptista Research) Read more: https://www.smartkarma.com/insights/fcn-us-segment-performance-revenue-diversity-as-a-crucial-factor-for-sustained-performance
0 · Reply
UncleStock
UncleStock Apr. 25 at 3:41 AM
$HUT $CUBI $FCN suggested for #blockchain - value screen: https://zpr.io/nAuVa
0 · Reply
TradeOtto46
TradeOtto46 Apr. 24 at 3:29 PM
WAKE UP — this setup is getting too obvious to ignore! 🚨🚨 We’re sitting near $3.10, and the 1-year analyst price target is $16.00 — that’s a projected +416% upside 📈 Rating? Strong Buy — no confusion, no debate. This is a conviction play. Last week’s move was just the beginning — we’re hearing high-confidence info from private sources: ⚠️ Major upside expected early next week — 100%+ move very much in play. And yes, the sources are legit. Microfloat, FDA catalyst, confirmed revenue, big-name partners (Thermo Fisher, Quest), and now? 📊 Analyst targets that scream undervalued. 🦍 I’m calling all $BOX , $FCN apes — you’ve seen what coordinated action can do. Hold off and drop your orders together — coordinated buys = max impact 💥 Let’s ignite this. Eyes on the breakout. Next week won’t wait. 🔥🚀 Not financial advice. But ignoring this? Might cost more than missing a trade.⁩
0 · Reply